Argenx's (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments [Yahoo! Finance]
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: Yahoo! Finance
on Argenx SE (NASDAQ:ARGX), citing robust sales growth in the company's Vyvgart brand. The firm reports that Vyvgart sales stay ahead of expectations and demonstrate solid momentum, which it expects to last through 2026 across authorized applications in MG (myasthenia gravis) and CIDP. The firm also emphasized the potential of Argenx's other clinical products, including empasiprubart in MMN (multifocal motor neuropathy), which the firm sees as having massive potential, with pivotal EMPASSION data coming in the fourth quarter of 2026. Moreover, the FDA recently agreed to give priority review to a supplemental biologics licensing application for Vyvgart. The application aims to increase Vyvgart's usage in treating adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG), increasing the patient group eligible for the drug. Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates th
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone [Yahoo! Finance]Yahoo! Finance
- argenex (NASDAQ:ARGX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- argenex (NASDAQ:ARGX) had its "hold (c)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- argenex (NASDAQ:ARGX) had its price target raised by analysts at Wells Fargo & Company from $1,264.00 to $1,317.00. They now have an "overweight" rating on the stock.MarketBeat
- argenex (NASDAQ:ARGX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $1,000.00 price target on the stock.MarketBeat
ARGX
Earnings
- 10/30/25 - Beat
ARGX
Sec Filings
- 1/13/26 - Form 6-K
- 1/12/26 - Form 6-K
- 1/5/26 - Form 6-K
- ARGX's page on the SEC website